- Home
- HYB vs CHRS Comparison
HYB vs CHRS Comparison
Compare HYB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYB
- CHRS
- Stock Information
- Founded
- HYB 1987
- CHRS 2010
- Country
- HYB United States
- CHRS United States
- Employees
- HYB N/A
- CHRS N/A
- Industry
- HYB Investment Managers
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYB Finance
- CHRS Health Care
- Exchange
- HYB Nasdaq
- CHRS Nasdaq
- Market Cap
- HYB 191.2M
- CHRS 191.3M
- IPO Year
- HYB 1999
- CHRS 2014
- Fundamental
- Price
- HYB $8.20
- CHRS $1.24
- Analyst Decision
- HYB
- CHRS Strong Buy
- Analyst Count
- HYB 0
- CHRS 4
- Target Price
- HYB N/A
- CHRS $5.38
- AVG Volume (30 Days)
- HYB 39.6K
- CHRS 2.0M
- Earning Date
- HYB 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- HYB 6.67%
- CHRS N/A
- EPS Growth
- HYB N/A
- CHRS N/A
- EPS
- HYB N/A
- CHRS N/A
- Revenue
- HYB N/A
- CHRS $304,340,000.00
- Revenue This Year
- HYB N/A
- CHRS $2.47
- Revenue Next Year
- HYB N/A
- CHRS N/A
- P/E Ratio
- HYB N/A
- CHRS N/A
- Revenue Growth
- HYB N/A
- CHRS 44.19
- 52 Week Low
- HYB $6.23
- CHRS $0.66
- 52 Week High
- HYB $7.41
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- HYB 47.55
- CHRS 37.51
- Support Level
- HYB $8.15
- CHRS $1.38
- Resistance Level
- HYB $8.27
- CHRS $1.45
- Average True Range (ATR)
- HYB 0.06
- CHRS 0.13
- MACD
- HYB -0.00
- CHRS -0.04
- Stochastic Oscillator
- HYB 40.00
- CHRS 4.50
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.